Streetwise Reports' Article Archives — Current Month (7)
Biotech Company Advances Breakthrough Hyperinsulinism Treatment (02/13/2026)
Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy.
Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar? (02/10/2026)
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent.
CleanTech Company Advances FDA-Cleared Solution Toward Big Gains (02/10/2026)
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.
Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies (02/09/2026)
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.
FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results (02/06/2026)
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study.
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study (02/02/2026)
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.
Biopharma Reaches 50% Enrollment in New ALS Drug Program (02/02/2026)
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.
More Archives
2026Jan
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
